Imaging Evaluation of Pulmonary and Non-Ischaemic Cardiovascular Manifestations of COVID-19

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Aug 7

PMID 34359355

Citations 6

Authors

Sebastiano Cicco

Antonio Vacca

Christel Cariddi

Rossella Carella

Gianluca Altamura

Antonio Giovanni Solimando

Gianfranco Lauletta

Fabrizio Pappagallo

Anna Cirulli

Assunta Stragapede

Nicola Susca

Salvatore Grasso

Roberto Ria

Affiliations

Soon will be listed here.

Abstract

Coronavirus Disease 2019 (COVID-19) has been a pandemic challenge for the last year. Cardiovascular disease is the most described comorbidity in COVID-19 patients, and it is related to the disease severity and progression. COVID-19 induces direct damage on cardiovascular system, leading to arrhythmias and myocarditis, and indirect damage due to endothelial dysfunction and systemic inflammation with a high inflammatory burden. Indirect damage leads to myocarditis, coagulation abnormalities and venous thromboembolism, Takotsubo cardiomyopathy, Kawasaki-like disease and multisystem inflammatory syndrome in children. Imaging can support the management, assessment and prognostic evaluation of these patients. Ultrasound is the most reliable and easy to use in emergency setting and in the ICU as a first approach. The focused approach is useful in management of these patients due its ability to obtain quick and focused results. This tool is useful to evaluate cardiovascular disease and its interplay with lungs. However, a detailed echocardiography evaluation is necessary in a complete assessment of cardiovascular involvement. Computerized tomography is highly sensitive, but it might not always be available. Cardiovascular magnetic resonance and nuclear imaging may be helpful to evaluate COVID-19-related myocardial injury, but further studies are needed. This review deals with different modalities of imaging evaluation in the management of cardiovascular non-ischaemic manifestations of COVID-19, comparing their use in emergency and in intensive care.

Citing Articles

A Novel Automatic Algorithm to Support Lung Ultrasound Non-Expert Physicians in Interstitial Pneumonia Evaluation: A Single-Center Study.

Marozzi M, Cicco S, Mancini F, Corvasce F, Lombardi F, Desantis V Diagnostics (Basel). 2024; 14(2).

PMID: 38248032 PMC: 10814651. DOI: 10.3390/diagnostics14020155.

Immune disturbance leads to pulmonary embolism in COVID-19 more than classical risk factors: a clinical and histological study.

Cicco S, Vacca A, Albanese F, Susca N, Desantis V, Magistro A Intern Emerg Med. 2023; 18(7):1981-1993.

PMID: 37592135 PMC: 10543807. DOI: 10.1007/s11739-023-03383-9.

Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study.

Cicco S, Marozzi M, Palumbo C, Sturda E, Fusillo A, Scarilli F Medicina (Kaunas). 2023; 59(2).

PMID: 36837405 PMC: 9962749. DOI: 10.3390/medicina59020203.

Cardiovascular Risk Score and Pulmonary Gas Exchange in COVID-19 Patients Show No Correlation.

Cicco S, Mozzini C, Carella R, De Fazio G, Vacca A, Cariddi C Adv Exp Med Biol. 2022; 1395:105-109.

PMID: 36527622 DOI: 10.1007/978-3-031-14190-4_18.

Pulmonary Embolism in COVID-19 Patients Is Not Related to a Deterioration of Tissue Oxygenation.

Cicco S, Albanese F, Didonna R, Magistro A, Vacca A, Cariddi C Adv Exp Med Biol. 2022; 1395:99-103.

PMID: 36527621 DOI: 10.1007/978-3-031-14190-4_17.

References

Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F . Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020; 41(22):2070-2079. PMC: 7239100. DOI: 10.1093/eurheartj/ehaa408. View

Gkoutzourelas A, Bogdanos D, Sakkas L . Kawasaki Disease and COVID-19. Mediterr J Rheumatol. 2020; 31(Suppl 2):268-274. PMC: 7656130. DOI: 10.31138/mjr.31.3.268. View

Inciardi R, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D . Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):819-824. PMC: 7364333. DOI: 10.1001/jamacardio.2020.1096. View

Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D . COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020; 201(10):1299-1300. PMC: 7233352. DOI: 10.1164/rccm.202003-0817LE. View

Mast T, Taha K, Cramer M, Lumens J, van der Heijden J, Bouma B . The Prognostic Value of Right Ventricular Deformation Imaging in Early Arrhythmogenic Right Ventricular Cardiomyopathy. JACC Cardiovasc Imaging. 2018; 12(3):446-455. DOI: 10.1016/j.jcmg.2018.01.012. View

Cheng X, Yu X, Ding Y, Fu Q, Xie J, Tang T . The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008; 127(1):89-97. DOI: 10.1016/j.clim.2008.01.009. View

Viecca M, Radovanovic D, Forleo G, Santus P . Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res. 2020; 158:104950. PMC: 7244436. DOI: 10.1016/j.phrs.2020.104950. View

Tang B, Shojaei M, Teoh S, Meyers A, Ho J, Ball T . Neutrophils-related host factors associated with severe disease and fatality in patients with influenza infection. Nat Commun. 2019; 10(1):3422. PMC: 6668409. DOI: 10.1038/s41467-019-11249-y. View

Kawasaki T, Singh S . Kawasaki disease - the journey over 50 years: 1967-2017. Int J Rheum Dis. 2017; 21(1):7-9. DOI: 10.1111/1756-185X.13215. View

10.

Cicco S, Cicco G, Racanelli V, Vacca A . Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. Mediators Inflamm. 2020; 2020:7527953. PMC: 7366221. DOI: 10.1155/2020/7527953. View

11.

Cajanding R . Comprehensive Review of Cardiovascular Involvement in COVID-19. AACN Adv Crit Care. 2021; 32(2):169-187. DOI: 10.4037/aacnacc2021302. View

12.

Solimando A, Susca N, Borrelli P, Prete M, Lauletta G, Pappagallo F . Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department. Front Med (Lausanne). 2021; 7:625176. PMC: 7854700. DOI: 10.3389/fmed.2020.625176. View

13.

Feldstein L, Rose E, Horwitz S, Collins J, Newhams M, Son M . Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020; 383(4):334-346. PMC: 7346765. DOI: 10.1056/NEJMoa2021680. View

14.

Leone P, Cicco S, Prete M, Solimando A, Susca N, Crudele L . Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. Clin Exp Med. 2019; 20(1):11-19. DOI: 10.1007/s10238-019-00600-8. View

15.

Labovitz A, Noble V, Bierig M, Goldstein S, Jones R, Kort S . Focused cardiac ultrasound in the emergent setting: a consensus statement of the American Society of Echocardiography and American College of Emergency Physicians. J Am Soc Echocardiogr. 2010; 23(12):1225-30. DOI: 10.1016/j.echo.2010.10.005. View

16.

Bonaventura A, Vecchie A, Dagna L, Martinod K, Dixon D, Van Tassell B . Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021; 21(5):319-329. PMC: 8023349. DOI: 10.1038/s41577-021-00536-9. View

17.

Lippi G, Lavie C, Sanchis-Gomar F . Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020; 63(3):390-391. PMC: 7127395. DOI: 10.1016/j.pcad.2020.03.001. View

18.

Pontone G, Scafuri S, Mancini M, Agalbato C, Guglielmo M, Baggiano A . Role of computed tomography in COVID-19. J Cardiovasc Comput Tomogr. 2020; 15(1):27-36. PMC: 7473149. DOI: 10.1016/j.jcct.2020.08.013. View

19.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

20.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View